PHM Stock Overview
A biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Pharma Mar, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €34.12 |
| 52 Week High | €43.00 |
| 52 Week Low | €26.34 |
| Beta | -0.088 |
| 1 Month Change | 22.65% |
| 3 Month Change | -2.96% |
| 1 Year Change | -5.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -49.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHM | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 7.6% | -1.8% | 2.5% |
| 1Y | -5.0% | -13.3% | 10.7% |
Return vs Industry: PHM exceeded the Austrian Biotechs industry which returned -14.2% over the past year.
Return vs Market: PHM underperformed the Austrian Market which returned 8.2% over the past year.
Price Volatility
| PHM volatility | |
|---|---|
| PHM Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in AT Market | 5.3% |
| 10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: PHM has not had significant price volatility in the past 3 months.
Volatility Over Time: PHM's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 509 | Jose Fernandez Sousa-Faro | www.pharmamar.com |
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer.
Pharma Mar, S.A. Fundamentals Summary
| PHM fundamental statistics | |
|---|---|
| Market cap | €600.81m |
| Earnings (TTM) | €1.14m |
| Revenue (TTM) | €158.15m |
528.4x
P/E Ratio3.8x
P/S RatioIs PHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHM income statement (TTM) | |
|---|---|
| Revenue | €158.15m |
| Cost of Revenue | €9.61m |
| Gross Profit | €148.54m |
| Other Expenses | €147.40m |
| Earnings | €1.14m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.064 |
| Gross Margin | 93.92% |
| Net Profit Margin | 0.72% |
| Debt/Equity Ratio | 20.6% |
How did PHM perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield1,023%
Payout RatioDoes PHM pay a reliable dividends?
See PHM dividend history and benchmarks| Pharma Mar dividend dates | |
|---|---|
| Ex Dividend Date | Jun 12 2024 |
| Dividend Pay Date | Jun 14 2024 |
| Days until Ex dividend | 27 days |
| Days until Dividend pay date | 29 days |
Does PHM pay a reliable dividends?
See PHM dividend history and benchmarks